AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

INSPIRATION HEALTHCARE GROUP PLC

Legal Proceedings Report Dec 31, 2019

7711_rns_2019-12-31_58e40705-f53d-4cc9-8d31-f4b2e7b8630e.html

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3259Y

Inspiration Healthcare Group PLC

31 December 2019

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

NPXe Files Voluntary Chapter 11 to implement Asset Sale

Inspiration Healthcare Group plc (AIM:IHC), the global medical technology company has been made aware that NPXe Limited ("NPXe") a company in which Inspiration Healthcare holds circa 8.6% of the issued share capital, that NPXe has filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. NPXe has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.

NPXe is a Phase III pharmaceutical and drug delivery device company developing XENEX™ (xenon gas for inhalation) for neuro- and cardio-protection and improvement in survival for post-cardiac arrest syndrome.

For further information on the process and timetable, please contact NeuroproteXeon directly (www.npxe.com).

Inspiration Healthcare's holding in NPXe is currently valued at £111,000 on its balance sheet. Should the sale of NXPe proceed the Company will issue a further statement  to update shareholders on details of any proceeds receivable from the sale.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Enquiries:

Inspiration Healthcare Group plc

Neil Campbell, Chief Executive Officer

Mike Briant, Chief Financial Officer
Tel: 01455 840555
Nominated Adviser & Broker

Cenkos Securities plc

Mark Connelly / Stephen Keys

Cameron MacRitchie
Tel: 0207 397 8900
Cadogan PR                                                                                         

Alex Walters

[email protected]
Tel: 07771 713608

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies. 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products.  This is supported by Technical Support for planned preventative maintenance and emergency assistance.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCFDIEESFUSEDE

Talk to a Data Expert

Have a question? We'll get back to you promptly.